We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.50 | 0.65% | 385.00 | 380.00 | 390.00 | 385.00 | 385.00 | 385.00 | 1,292 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 41.93M | 6.49M | 0.1361 | 28.29 | 182.42M |
Tristel plc
("Tristel" or the "Company")
Exercise of Share Options and Total Voting Rights
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a total of 6,500 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Group.
Application has been made to the London Stock Exchange for the 6,500 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 27 November 2024.
Total Voting Rights
After Admission, the total number of Ordinary Shares in issue will be 47,692,093 and the total number of voting rights will therefore be 47,692,093. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
Tristel plc |
Via Walbrook PR |
|
Matt Sassone, Chief Executive Officer |
||
Liz Dixon, Chief Financial Officer |
|
|
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or tristel@walbrookpr.com |
|
Paul McManus |
Mob: 07980 541 893 |
|
Charlotte Edgar |
Mob: 07884 664 686 |
|
|
|
|
Cavendish Capital Markets Limited |
Tel: 020 7220 0500 |
|
Geoff Nash / Camilla Hume / Trisyia Jamaludin (Corporate Finance) |
|
|
Sunila de Silva (ECM) Louise Talbot (Sales) |
|
|
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com
1 Year Tristel Chart |
1 Month Tristel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions